[{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Nephrology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Recordati Rare Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Recordati Rare Diseases"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Aldosterone synthase (CYP11B2)||Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Aldosterone synthase (CYP11B2)||Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Osilodrostat Phosphate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
